Dynavax Technologies (NASDAQ:DVAX) Downgraded by The Goldman Sachs Group to “Sell”

The Goldman Sachs Group lowered shares of Dynavax Technologies (NASDAQ:DVAX) from a neutral rating to a sell rating in a report published on Tuesday, MarketBeat.com reports. They currently have $12.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $15.00.

Other equities research analysts have also issued research reports about the stock. HC Wainwright boosted their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $12.70 on Tuesday. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of 97.70 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $13.89. The firm has a 50-day moving average of $12.81 and a two-hundred day moving average of $11.91.

Institutional Trading of Dynavax Technologies

Several large investors have recently made changes to their positions in DVAX. Smartleaf Asset Management LLC boosted its holdings in Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares during the last quarter. US Bancorp DE raised its position in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter valued at about $45,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,679 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.